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Objectives. This clinical study was designed to compare rate. 
dependent effects of class III agents on QT prolongation. 
Background. Clinical data that compare the electrophysiologic 
differences among class III agents with different selectivity for 
potassium channels are still lacking. 
Methods. QT intervals were measured over a wide range of 
preceding RR intervals during sinus rhythm by 24-h Holter 
electrocardiography before and after oral administration of four 
class III agents: E4031, dofetilide, MS551 and d-sotalol. Rate- 
dependent changes in the QT interval were assessed by the slope 
of the linear regression line estimating the QT-~ relation. 
Results. All agents significantly increased the mean slope: 
E4031 increased the mean [-+SD] value from 0.32 _+ 0.05 to 0.42 _+ 
0.13 (p < 0.01), dofetilide from 0.32 +- 0.03 to 0.50 -+ 0.12 (p < 
0.03), MS551 from 0.35 -+ 0.06 to 0.45 -+ 0.10 (p < 0.02) and 
d-sotalol from 0.31 -+ 0.05 to 0.33 -+ 0.04 (p < 0.05). However, in 
those patients given either E4031, dofetilide or MS551, the degree 
of QT prolongation was smaller at shorter ~ intervals and was 
better preserved at shorter ~ intervals by d.sotalol, with a 
smaller increase in slope (p < 0.02 vs. dofetilide and MS551). 
Conclusions. On ambulatory electrocardiography, reverse use 
dependence in QT prolongation was least prominent with d- 
sotalol among the four study drugs. In the range of physiologic 
heart rates, class III agents could manifest different profiles of 
rate dependence in their QT-prolonging effect. 
(2] Am Coil Cardiol 1996;27:84-9) 
The decline in class III action at faster heart rates has been 
attributed to a phenomenon called reverse use-dependent 
block (1-3). Among currently available class III agents, some 
exhibit a nonspecific ardiac potassium channel-blocking ef- 
fect, whereas others block the delayed rectifier current selec- 
tively (3). Furthermore, recent animal studies suggest (4,5) 
that differences in selectivity for the blockade of each potas- 
sium channel can at least partially determine the manifestation 
of reverse use-dependent blocking action. 
Although various class III antiarrhythmic drugs have been 
evaluated in animal and human studies, clinical data that 
compare the electrophysiologic differences among these agents 
are still lacking. We previously showed (6) that the clinical 
determination f reverse use-dependent QT prolongation by 
disopyramide and E4031 by means of 24-h Holter electrocar- 
diography was useful in evaluating antiarrbythmic efficacy. In 
that report, we assessed the reverse use dependence by 
using the slope of the linear regression line estimating the 
QT-',/RR relation. 
In the present study, using a similar approach, we tried to 
assess differences in the rate dependence of QT prolongation 
From the Cardiopulmonary Division, Department of Medicine, Keio Uni- 
versity School of Medicine, Tokyo, Japan. 
Manuscript received April 14,1995; revised manuscript received July 7, 1995, 
accepted August 10, 1995. 
Address for corresnondence: Dr. Yutaka Okada, Division of Cardiology, 
Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108, Japan. 
by four class III agents: E4031, dofetilide, MS551 and d- 
sotalol. 
Methods  
Patients. Thirty-six consecutive patients (mean [_+SD] age 
53 _+ 14 years, range 29 to 79; 21 men, 15 women) whose 
symptomatic arrhythmias were treated with class III antiar- 
rhythmic drugs at our hospital were studied. The administered 
agents were as follows: E4031 (1.5 to 3.0 mg twice a day) in 11 
patients; dofetilide (0.5 to 0.75 mg twice a day) in 8; MS551 
(100 to 150 mg three times a day or 150 mg four times a day) 
in 7; and d-sotalol (100 to 200 mg twice a day) in 10. Of these 
36 patients, 6 had organic heart disease (coronary artery 
disease in 1, valvular heart disease in 4, cardiac sarcoidosis in 
1). The remaining 30 patients did not have organic heart 
disease as determined by physical examination, exercise test 
and echocardiographic examination. Arrhythmias treated 
were frequent premature ventricular contractions (->1,000 
beats/day) in27 patients, ustained ventricular tachycardia in 2, 
supraventricular premature contractions/paroxysmal upraven- 
tricular tachycardia n 5 and paroxysmal trial fibrillation in 2. 
All patients gave informed consent. The study protocol was 
approved by the Ethical Committee of Keio University. 
Measurements of intervals using 24-h Holter electro- 
cardiography. Twenty-four hour Holter electrocardiograms 
(ECGs) were recorded before and 2 to 4 weeks after oral 
administration of drugs. On each recording (lead CC 5 or 
CMs), we measured 100 to 150 QT intervals over a wide range 
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of preceding RR intervals (between 500 and 1,200 ms) during 
sinus rhythm, at a paper speed of 25 mm/s. These measure- 
ments were made manually and separately by two of the 
authors (Y.O., T.S.) who were unaware of the treatment 
received, and three replicate measurements were made by 
each reader. We selected beats occurring within 8 h after each 
dose for measurement of these variables in patients receiving 
E4031, dofetilide and d-sotalol with plasma half-lives of 6 to 8, 
7 to 8 and 7 to 9 h, respectively. In patients receiving MS551, 
with a shorter half-life of 1.5 h, these values were measured in
QRS complexes within 2 h after each administration. All ECGs 
recorded within the plasma half-life were used to examine rate 
dependence in drug-induced QT prolongation. The end of the 
T wave was defined according to the criteria of Lepeschkin and 
Surawicz (7): when the U wave merged with the T wave, it was 
defined as the point where the tangential line drawn to the 
descending limb of the T wave crossed the baseline. 
Assessment of reverse use.dependent QT prolongation. 
The QT intervals were plotted against he preceding 
intervals with the formula QT = K~/RR + A, where K is the 
slope, and A is the intercept of the linear regression line. The 
slope (K) of this regression line was used for assessment of
rate-dependent changes of QT prolongation. In our previous 
study (6), the mean slope in 38 control patients who did not 
take any antiarrhythmic drugs was 0.30 _+ 0.05 (mean _+ SD), 
and the criterion for positive reverse use-dependent QT pro- 
longation was defined as a slope ->0.40 (mean + 2 SD) after 
drug administration. 
Measurement of corrected QT (QTc) interval in 12-lead 
ECGs. The QTc intervals were calculated according to Ba- 
zetts' equation, using standard 12-lead ECGs recorded at a 
paper speed of 25 mm/s before and 2 to 4 weeks after drug 
administration. Measurements were made manually in the 
single lead with the longest QT interval before drug therapy 
and was repeated in the same lead after drug administration. 
Statistical analysis. The Wilcoxon signed-ranks test was 
used to compare paired data before and after each drug 
treatment. Comparisons among the four treatment groups 
were made as follows: An unpaired Student or Welch t test was 
used to compare ach pair of the mean slopes obtained uring 
drug treatment separately. The other multiple comparisons 
were made with factorial analysis of variance with the Scheff6 
F test. The significance of regression between the QT and 
intervals was determined by analysis of covariance. All 
group data are presented as mean _+ SD; p < 0.05 was 
accepted as statistically significant. 
Resu l ts  
Effects of drugs on QTc prolongation on standard 12.lead 
ECG. The QTc intervals could not be accurately determined 
in six patients (four given E4031 and one each given MS551 or 
d-sotalol) because of frequent premature ventricular or su- 
praventricular contractions. One patient receiving dofetilide 
was excluded because of the presence of complete right 
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Figure 1. Changes in QTc interval measured with standard 12-lead 
electrocardiography at baseline and during each drug administration. 
n = number of patients. Vertical ines = mean value _+ SD. *p < 0.05 
versus baseline. 
bundle-branch block. Data for the other 29 patients were 
analyzed. 
Figure 1 shows changes in the QTc interval before and after 
the administration of each drug. The mean QTc intervals 
before receiving E4031, dofetilide, MS551 and d-sotalol were 
420 + 22, 396 + 15, 411 + 22 and 405 + 35 ms, respectively. 
Although longer QYc intervals (->440 ms) were observed in 
three patients, including two given E4031 (440 and 450 ms) and 
one given d-sotalol (460 ms), the differences among the four 
treatment groups were not statistically significant. During drug 
therapy, the QTc interval was prolonged in 27 of the 29 
patients and did not change in the other 2 patients treated with 
E4031 and d-sotalol, respectively. E4031, dofetilide, MS551 
and d-sotalol all prolonged mean QTc intervals ignificantly to 
468 _+ 41 ms (by 11.4 + 6.9%), 457 _+ 30 ms (by 15.4 _+ 6.7%), 
458 _+ 29 ms (by 11.4 _+ 4.5%) and 451 + 33 ms (by 11.6 + 
6.5%), respectively (p < 0.03 in MS551, and p < 0.02 in the 
other three groups). The degree of QTc prolongation was not 
significantly different among these drugs. 
Rate-dependent effect of drugs on QT prolongation on 24-h 
Holter ECGs. Holter recording at baseline was not obtained 
in one patient given d-sotalol. In two patients given dofetilide, 
measurement of QT intervals was considered to be inaccurate 
because of a flattened T wave. Data for the remaining 33 
patients were analyzed. The correlation coefficient of the 
linear egression line estimating the QT-~/RR relation ranged 
from 0.71 to 0.94 before and after administration f each drug. 
Figure 2 shows representative QT-~-RR relation with each 
agent. In patients given E4031, dofetilide and MS551, the slope 
of the regression line increased uring drug therapy; these 
agents prolonged the QT interval increasingly as the preceding 
interval engthened. In contrast, he effect of d-sotalol 
on QT prolongation was not confined to QRS complexes with 
longer ~ intervals. As shown with a lesser degree of 
increase of the slope in the patient with d-sotalol, the QT 
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Figure 2. Linear egression li es estimating 
the QT-VRR relation before (open circles) 
and after drug administration (solid circles) 
in representative cases for each agent. K = 
slope of regression li e for each patient. 
prolongation at shorter preceding X/RR intervals was better 
preserved by d-sotalol than that by the other three agents. 
This result indicates that d-sotalol exhibited the least re- 
verse use dependence in QT prolongation among the four 
study drugs. 
Figure 3, Change in slope of linear regression line estimating the 
QT-%/RR relation at baseline (open bars) and during drug adminis- 
tration (solid bars). Data shown are mean value _+ SD. *p < 0.05, 
**p < 0.01 versus baseline. +p < 0.05 versus after administration of 
d-sotalol. Abbreviations a in Figure 1. 
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Figures 3 and 4 summarize changes in the slope during drug 
therapy. At baseline, the mean slope was 0.32 _+ 0.05, 0.32 _+ 
0.03, 0.35 _+ 0.06 and 0.31 _+ 0.05 in patients given E4031, 
dofetilide, MS551 and d-sotalol, respectively. Although two 
patients (one given MS551, the other given d-sotalol) had 
slopes ->0.40 (0.45 and 0.40, respectively), there were no 
differences among the four patient groups. 
During drug therapy, all agents ignificantly increased the 
mean slope. E4031 increased the mean value to 0.42 _+ 0.13 
(p < 0.01), dofetilide to 0.50 _+ 0.12 (p < 0.03), MS551 to 
0.45 _+ 0.10 (p < 0.02) and d-sotalol to 0.33 _+ 0.04 (p < 0.05). 
The level of significance of change in the mean value in 
d-sotalol group was smaller than that in the other three groups. 
The mean slope after administration f d-sotalol was signifi- 
cantly (p < 0.02) smaller than that after administration f
dofetilide and MS551. Whereas the mean slope in patients 
with E4031 was also larger than that in patients with d-sotalol, 
this difference did not reach statistical significance (p = 0.054). 
Among the three agents other than d-sotalol, the mean slopes 
obtained uring the administration were not significantly dif- 
ferent. 
When the criterion for positive reverse use-dependent QT
prolongation was defined as a slope K ->0.40 after drug 
administration, positive reverse use dependence was recog- 
nized most frequently in patients treated with dofetilide (5 
[83%] of 6 patients), followed by E4031 and MS551 (7 [64%] 
of 11 and 4 [57%] of 7, respectively). In contrast, only one 
patient given d-sotalol demonstrated positive reverse use de- 
pendence (1 [11%] of 9). 
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Figure 4. Changes in slope of regression 
line estimating the QT-VRR relation be- 
fore and after administration f each drug. 
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Discuss ion  
In the present study, we examined the reverse use- 
dependent QT prolongation by four class III agents--E4031, 
dofetilide, MS551 and d-sotalol--in the range of physiologic 
RR intervals (between 500 and 1,200 ms) by using 24-h Holter 
ECGs. These agents prolonged the QTc interval by a similar 
degree in standard 12-lead ECGs. However, the reverse use 
dependence in QT prolongation was least prominent with 
d-sotalol and occurred in descending order of frequency: 
dofetilide > E4031 and MS551 >> d-sotalol. 
Possible mechanism of reverse use-dependent blocking 
action by class III agents. Colatsky et al. (3) summarized the 
specificity of various antiarrhythmic drugs for each potassium 
channel (I K [delayed rectifier current], IK1 [inward rectifier 
current] and Ito [transient outward current]) by reviewing the 
results from previous animal studies. In that report, E4031 and 
UK68798 (dofetilide) were shown to be selective I K blocking 
agents, and amiodarone was considered to be an IK and IKI 
blocker. In contrast, sotalol, disopyramide and quinidine were 
considered to block I K, IKl and Ito nonselectively. Further- 
more, E4031, dofetilide and d-sotalol were shown to block a 
rapid component of IK (IKr) preferentially (8-10). However, 
amiodarone, with use-independent class III action, was found 
to block a slow component of IK (Ii<,) (11). 
Animal studies using selective IKr blockers (4,5) have 
demonstrated that reverse use-dependent block would be 
explained not by an intrinsic reverse use dependence of I~ 
blockade but by a concomitant increase in other repolarizing 
currents. Jurkiewicz and Sanguinetti (4) showed that IKs 
accumulation during rapid pacing, because of its slow deacti- 
vation kinetics, could diminish the rate-independent block of 
IKr by dofetilide and result in the drug's reverse use depen- 
dence. 
The increase in IK~ by extracellular potassium accumulation 
during rapid pacing in multicellular preparations may also 
contribute to the rate-dependent shortening of action potential 
duration and diminish the impact of the Ii~ blockade during 
rapid heart rates. Rces and Curtis (12) demonstrated, in
isolated rat heart, that the specific IK1 blocker RP58866 
prolonged the QT interval, and this prolongation was not 
affected by rapid pacing. 
Although a selective Ito blocker is not available currently, 
electrophysiologic properties of Ito were reported in human 
vcntricular myocytes of terminal heart failure (13). In that 
report, frequency-dependent reduction of Ito by -30% was 
observed at cardiac pacing of 2 Hz, possibly as a result of the 
slow component of its reactivation. Therefore, unlike I~, Ito 
will not contribute to a rate-dependent shortening of action 
potential duration. 
These experimental studies uggest hat pure Ii~ blockers 
exhibit more pronounced reverse use dependence because of 
the increased contribution of IKs or IK1 tO the net repolariza- 
tion current at faster heart rates. In contrast, drugs that block 
IKs or IKI preferentially may manifest less reverse use 
dependence. As we previously showed (6), disopyramide 
(300 mg/day), which is a nonselective potassium channel 
blocker like sotalol (3), increased the mean slope K from 
0.28 + 0.04 to 0.35 _+ 0.08, and a slope ->0.40 was recognized 
in 8 (40%) of 20 patients treated with disopyramide. There- 
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fore, patients given disopyramide manifested less reverse use- 
dependent QT prolongation than did patients given E4031, 
dofetilide or MS551 in the present study. Our observation that 
reverse use-dependent QT prolongation is more prominent 
with class III agents with higher selectivity for Ir, r than with 
nonselective potassium channel blockers is partially consistent 
with the findings in animal models. Although the contribution 
of other channels to repolarization should become increasingly 
important at faster heart rates, clinically relevant differences in
rate-dependent effects on QT prolongation may exist among 
class III agents with a different selectivity of blockade for 
potassium channels. 
In addition, Wallace et al. (14) showed differences among 
agents in relative potency of class III activity itself. They 
showed, using canine ventricle, that effects of agents on 
prolongation of effective refractory period and QT interval 
decreased sequentially, so that UK68798 (dofetilide) > 
E4031> d-sotalol. These results are also in accord with our 
observations. 
Potential limitations of the study. The dose of d-sotalol 
used in our study was lower than that of sotalol used in the 
previous human studies (15,16) that showed that sotalol pro- 
longed QT interval or duration of monophasic action poten- 
tials in a reverse use-dependent manner. Funck-Brentano etal. 
(15) evaluated QT prolongation i normal volunteers receiving 
sotalol during a treadmill exercise test; sotalol was shown to 
prolong the QTc interval by 4.3 _+ 3.4% at 160 rag/day (p = 
NS), 5.8 _+ 3.7% at 320 rag/day (p < 0.01) and 11.8 + 3% at 
640 rag/day (p < 0.01). In the present study, d-sotalol pro- 
longed the QYc interval by 11.6 + 6.5% (p < 0.02), which was 
comparable to prolongation by the other three drugs. Plasma 
drug concentration was not determined in our study. There- 
fore, we measured the QT and preceding RR intervals in QRS 
complexes occurring within the plasma half-life of each agent 
after each administration. 
Autonomic tone, especially vagal tone, may have influenced 
differently between patients treated with d-sotalol and those 
receiving the other three agents. Of six patients with organic 
heart disease in this study, four belonged to the d-sotalol- 
treated group. In human studies (17,18), vagal activity has been 
shown to prolong the QT interval independent of heart rates. 
Thus, the possibility cannot be ruled out that the reverse 
use-dependent QT prolongation by d-sotalol in our study 
might have been masked in patients in whom vagal tone was 
compromised by coexisting heart disease. Although evaluation 
of heart rate variability has been shown to be a useful method 
for clinical assessment of autonomic tone, it was not suitable 
for use in our study because of the presence of _>1,000 pre- 
mature ventricular contractions/day. 
The number of measurements on 24-h Holter electrocar- 
diography tended to be few in patients with frequent bigeminy 
cycles of premature ventricular contractions because care was 
taken not to measure QT intervals preceded by premature 
beats. Furthermore, the range of measured preceding x/RP, 
intervals tended to be narrow in some patients receiving 
MS551 because the measurements were performed in QRS 
complexes within only 2 h after each administration. Despite 
these limitations, a correlation coefficient of the regression line 
estimating QT-V~RR relation still exceeded 0.7 in those cases. 
Clinical implications. The proarrhythmic actions of the 
class Ic agents have been refocused since the publication of 
the Cardiac Arrhythmia Suppression Trial (CAST) study (19). 
The Electrophysiologic Study Versus Electrocardiographic 
Monitoring (ESVEM) study (20) recently showed that sotalol 
was more effective than several class I agents in managing 
patients with ventricular tachyarrhythmias. According to a 
controlled prospective study that compared the antiarrhythmic 
effect of sotalol with that of amiodarone (21), both agents 
appeared to exhibit similar long-term efficacy in treating 
chronic malignant ventricular tachyarrhythmias. Drugs such as 
amiodarone and sotalol may be expected to be more useful 
clinically than other agents with class III activity because of 
their less reverse use-dependent blocking actions as well as 
their positive inotropic action and the ability to decrease QTc 
dispersion as measured with standard 12-lead electrocardio- 
graphy (22). 
Conversely, the Survival With Oral d-Sotalol (SWORD) 
trial (23) for survivors of a myocardial infarction with left 
ventricular dysfunction was prematurely terminated because of 
higher mortality in the drug-treated group than in the placebo 
group. In the SWORD trial, patients with malignant ventricu- 
lar arrhythmias were excluded; therefore, the risk/benefit ratio 
of d-sotalol in various patient groups who could be considered 
to be at a higher risk of sudden death, such as those in the 
ESVEM study, may be different. Results of the remaining 
studies of d-sotalol treatment in patients will be necessary to 
confirm the clinical efficacy of d-sotalol. 
Conclusions. Our observation that reverse use dependence 
in QT prolongation is least prominent with d-sotalol, with 
nonselective potassium channel blockade, among the class III 
drugs studied is partially consistent with findings in animal 
models. Also, in the range of physiologic RR intervals on 
ambulatory electrocardiography, class III agents could mani- 
fest different profiles of rate dependence in QT-prolonging 
effect. Because the number of our study patients was small, 
studies in larger patient groups are required to confirm 
whether clinically relevant differences exist among class III 
agents with different selectivity of blockade for potassium 
channels. 
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